Hospitalizations 'Extremely Uncommon' After COVID-19 Immunity

Fewer than 1 in 1,000 individuals who have been vaccinated or earlier infected with COVID-19 were hospitalized with a breakthrough infection.

Fewer than 1 in 1,000 individuals who have been vaccinated or earlier infected with COVID-19 were hospitalized with a breakthrough infection, found Mayo Clinic research.

"In the general primary care patient population, those who have been vaccinated have very low risk of subsequent hospitalization for breakthrough COVID-19," says lead author Benjamin Pollock, PhD, a researcher in the Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery. "Our study shows that while it can and does happen, that these occurrences are extremely uncommon."

Fluvoxamine: An OCD Drug can Prevent Covid-19 Patients from Hospitalization
Fluvoxamine has been proven among one such drug that could be used to treat COVID-19. Dozens of COVID patients showed no clinical deterioration in their symptoms when treated with a drug, fluvoxamine.

‘The study supports previous studies that show vaccination is the best way to prevent severe COVID-19 infection, hospitalization and death. ’

The researchers created a longitudinal study of 106,349 primary care patients at Mayo Clinic in Rochester who were 18 or older and tested positive for COVID-19, and/or were vaccinated for COVID-19. Of those patients, only 69 were hospitalized because of a breakthrough COVID-19 infection.

The researchers found the hospitalization rate was:

0.06%, or 6 in 10,000 for vaccinated patients.
0.03%, or 3 in 10,000, in previously infected but unvaccinated people.
0.01%, or 1 in 10,000, among those who were both vaccinated and infected previously.

While there were slight differences between the three groups, the researchers note the difference is not statistically significant.

"We found these results to be in line with previous studies, although the interpretation shouldn’t necessarily be that natural immunity provides the same protection as vaccination,” says Dr. Pollock. “Rather, this study found that among our primary care population, both natural immunity and vaccine immunity appeared to lead to very low rates of breakthrough hospitalizations."

Test your Knowledge on Coronavirus (COVID-19)
Coronavirus is a large positive-strand RNA virus that is surrounded by a protein envelope. The virus obtains its name from the S protein spikes on its surface, which resemble a crown. The overall pattern of increasing coronavirus cases is shown to spike up with the “second wave” of COVID-19.

With spiking effects of the second wave of coronavirus, the best way to keep it at bay is to follow COVID-appropriate safety practices like wearing a mask, regularly cleaning your hands, and coughing into a bent elbow or tissue along with physical distancing (6 feet about 2 arm's length), that may help evade the severity of COVID-19 infection.

The researchers looked at breakthrough cases that resulted in hospitalization, but they did not compare immunity after infection and vaccination rates among mild or asymptomatic breakthrough cases.

Study About Rare Neurological Events After COVID-19 Vaccination
The study found out that there was no increased risk of rare neurological events after the COVID-19 vaccines like Oxford-AstraZeneca or Pfizer covid vaccines.

"We know that vaccination remains the safest route to protection from COVID-19 infection and severe disease," says Aaron Tande, MD, a Mayo Clinic infectious diseases physician, and a co-author of the study. "I explain to my patients that a COVID-19 vaccine provides additional protection, even if they have been previously infected. For those who have not been infected, vaccination remains the safest and most reliable route of protection."

Previous studies have shown similar results, the researchers note. Some studies have shown that immunity after infection prevents the most hospitalizations. Other studies have shown that vaccination prevents the most hospitalizations. In both cases, breakthrough hospitalizations are similarly rare.

COVID-19 Vaccination: India's Coverage Crosses 180 Crore Milestone
COVID-19 vaccination coverage in India has crossed the 180 crore landmark. As per the Union Health Ministry report, over 17 lakh vaccine doses were administered.

"Because it’s impossible to tell in advance how severe a first infection may be, or who among vulnerable populations the virus may spread to, waiting for natural immunity is a gamble and not a safe alternative," Dr. Tande says.

The research was supported by the Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery. The center’s research focuses on transforming clinical practice. Its researchers seek to discover new ways to improve health; translate those discoveries into evidence-based, actionable treatments, processes and procedures; and apply this new knowledge to improve patient care.

The senior author of the study is Priya Sampathkumar, MD, a Mayo Clinic infectious diseases physician and head of Mayo’s Infection Prevention and Control Program. In addition to Dr. Tande, the study’s co-author is Curtis Storlie, PhD, a researcher in the Mayo Clinic Kern Center for the Science of Health Care Delivery.

The research was funded by Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery. The team reports no conflicts of interest.

Source-Eurekalert